ArticleInternational journal of general medicine2025
Elevated Lipoprotein(a) Predicts Stent Edge Restenosis and Adverse Two-Year Outcomes After PCI: An Intravascular Ultrasound Study.
Article in International journal of general medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Lipoprotein(a) in Coronary Artery Disease and Aortic Stenosis: Pathophysiology, Clinical Impact, Interventional Implications and Emerging Targeted Therapies.Journal of clinical medicine · 2026Review
- Lipoprotein(a), Coronary Complexity, and Stent-Related Outcomes: Meta-Analytic Insights for the Interventional Cardiologist.Journal of clinical medicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Elevated lipoprotein(a) [Lp(a)] is a known contributor to recurrent ischemic events following percutaneous coronary intervention (PCI). Although drug-eluting stents (DES) have significantly advanced coronary revascularization, stent edge restenosis (SER) remains a clinical challenge. However, the relationship between Lp(a) levels and the incidence of SER is not well defined. Objective: This study aimed to investigate the association between serum Lp(a) levels and the development of SER, and to explore potential pathophysiological mechanisms using intravascular ultrasound (IVUS). Methods: A total of 211 patients with SER lesions who underwent IVUS-guided PCI were included. Patients were divided into two groups based on their baseline Lp(a) concentrations: elevated Lp(a) (≥50 mg/dL, n=75) and non-elevated Lp(a) (<50 mg/dL, n=136). Clinical characteristics, angiographic features, IVUS findings, and device-oriented clinical endpoints (DoCE) were compared between the two cohorts. Results: Baseline clinical and angiographic characteristics were similar between the groups (P > 0.05). Neoatherosclerosis was significantly more frequent in the elevated Lp(a) group (56.0% vs 44.1%, P < 0.001), whereas neointimal hyperplasia was less common (24.0% vs 33.8%, P < 0.001). Multivariate analysis identified elevated Lp(a) as an independent predictor of SER (odds ratio: 3.391; 95% confidence interval: 2.030-5.273; P < 0.001). During a two-year follow-up, the elevated Lp(a) group showed higher rates of DoCE (16.0% vs 7.4%, P < 0.001) and target lesion revascularization (13.3% vs 5.1%, P = 0.011). Conclusion: Elevated Lp(a) is an independent predictor of SER and is associated with adverse two-year clinical outcomes after PCI. These findings underscore the importance of Lp(a) as a potential therapeutic target for improving long-term stent durability.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.